Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin

Type 2 diabetes mellitus (T2DM) has become a worldwide health problem, and the rate of it is growing greatly in the People’s Republic of China every year. T2DM could cause macrovascular and microvascular complications that lead to an increase in arterial wall thickness, endothelial dysfunction, calc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hongyu, Liu, Jinbo, Zhao, Hongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322603/
https://www.ncbi.nlm.nih.gov/pubmed/25678772
http://dx.doi.org/10.2147/DDDT.S53048
_version_ 1782356415381241856
author Wang, Hongyu
Liu, Jinbo
Zhao, Hongwei
author_facet Wang, Hongyu
Liu, Jinbo
Zhao, Hongwei
author_sort Wang, Hongyu
collection PubMed
description Type 2 diabetes mellitus (T2DM) has become a worldwide health problem, and the rate of it is growing greatly in the People’s Republic of China every year. T2DM could cause macrovascular and microvascular complications that lead to an increase in arterial wall thickness, endothelial dysfunction, calcification, and – finally – to an increase in arterial stiffness and arterial dysfunction. Alogliptin, a new selective inhibitor of dipeptidyl peptidase 4, has shown its great antihyperglycemia effect in T2DM patients. The clinical trial data from the People’s Republic of China was similar to other global and Asian trials. This could provide some choice for clinical physicians to the treatment of T2DM.
format Online
Article
Text
id pubmed-4322603
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43226032015-02-12 Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin Wang, Hongyu Liu, Jinbo Zhao, Hongwei Drug Des Devel Ther Review Type 2 diabetes mellitus (T2DM) has become a worldwide health problem, and the rate of it is growing greatly in the People’s Republic of China every year. T2DM could cause macrovascular and microvascular complications that lead to an increase in arterial wall thickness, endothelial dysfunction, calcification, and – finally – to an increase in arterial stiffness and arterial dysfunction. Alogliptin, a new selective inhibitor of dipeptidyl peptidase 4, has shown its great antihyperglycemia effect in T2DM patients. The clinical trial data from the People’s Republic of China was similar to other global and Asian trials. This could provide some choice for clinical physicians to the treatment of T2DM. Dove Medical Press 2015-01-30 /pmc/articles/PMC4322603/ /pubmed/25678772 http://dx.doi.org/10.2147/DDDT.S53048 Text en © 2015 Wang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Wang, Hongyu
Liu, Jinbo
Zhao, Hongwei
Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin
title Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin
title_full Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin
title_fullStr Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin
title_full_unstemmed Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin
title_short Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin
title_sort emerging options for the treatment of type 2 diabetes in chinese patients: focus on arterial function and alogliptin
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322603/
https://www.ncbi.nlm.nih.gov/pubmed/25678772
http://dx.doi.org/10.2147/DDDT.S53048
work_keys_str_mv AT wanghongyu emergingoptionsforthetreatmentoftype2diabetesinchinesepatientsfocusonarterialfunctionandalogliptin
AT liujinbo emergingoptionsforthetreatmentoftype2diabetesinchinesepatientsfocusonarterialfunctionandalogliptin
AT zhaohongwei emergingoptionsforthetreatmentoftype2diabetesinchinesepatientsfocusonarterialfunctionandalogliptin

Ejemplares similares